- Stocks
- Healthcare
- NASDAQ: AMPH

Price (delayed)

$58.3

Market cap

$2.79B

P/E Ratio

20.9

Dividend/share

N/A

EPS

$2.79

Enterprise value

$3.19B

Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active

The EPS has soared by 77% YoY and by 33% from the previous quarter

The net income has soared by 75% YoY and by 33% from the previous quarter

The stock's P/E is 81% less than its 5-year quarterly average of 109.1 but 6% more than its last 4 quarters average of 19.6

Amphastar Pharmaceuticals's quick ratio has surged by 51% QoQ but it has decreased by 36% YoY

AMPH's debt is up by 27% since the previous quarter

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Website: http://www.amphastar.com

What are the main financial stats of AMPH

Market
Valuations
Earnings

Shares outstanding

47.91M

Market cap

$2.79B

Enterprise value

$3.19B

Price to book (P/B)

4.79

Price to sales (P/S)

4.72

EV/EBIT

16.99

EV/EBITDA

14.76

EV/Sales

5.31

Revenue

$601.31M

EBIT

$187.97M

EBITDA

$216.41M

Free cash flow

$139.83M

Per share
Balance sheet
Liquidity

EPS

$2.79

Free cash flow per share

$2.87

Book value per share

$12.18

Revenue per share

$12.35

TBVPS

$19

Total assets

$1.54B

Total liabilities

$949.49M

Debt

$672.56M

Equity

$595.14M

Working capital

$285.04M

Debt to equity

1.13

Current ratio

2.1

Quick ratio

1.65

Net debt/EBITDA

1.86

Margins
Efficiency
Dividend

EBITDA margin

36%

Gross margin

54.2%

Net margin

22.5%

Operating margin

30.1%

Return on assets

12.2%

Return on equity

23.9%

Return on invested capital

24.6%

Return on capital employed

14.6%

Return on sales

31.3%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Amphastar Pharmaceuticals stock price performed over time

Intraday

0.14%

1 week

4.59%

1 month

24.49%

1 year

102.29%

YTD

108.07%

QTD

26.77%

How have Amphastar Pharmaceuticals's revenue and profit performed over time

Revenue

$601.31M

Gross profit

$326.15M

Operating income

$180.84M

Net income

$135.29M

Gross margin

54.2%

Net margin

22.5%

The operating income has surged by 93% year-on-year and by 38% since the previous quarter

The net income has soared by 75% YoY and by 33% from the previous quarter

AMPH's operating margin has soared by 55% year-on-year and by 24% since the previous quarter

AMPH's net margin is up by 42% year-on-year and by 20% since the previous quarter

What is Amphastar Pharmaceuticals's growth rate over time

What is Amphastar Pharmaceuticals stock price valuation

P/E

20.9

P/B

4.79

P/S

4.72

EV/EBIT

16.99

EV/EBITDA

14.76

EV/Sales

5.31

The stock's P/E is 81% less than its 5-year quarterly average of 109.1 but 6% more than its last 4 quarters average of 19.6

The EPS has soared by 77% YoY and by 33% from the previous quarter

The price to book (P/B) is 71% higher than the 5-year quarterly average of 2.8 and 33% higher than the last 4 quarters average of 3.6

Amphastar Pharmaceuticals's equity has increased by 18% YoY

AMPH's price to sales (P/S) is 57% more than its 5-year quarterly average of 3.0 and 24% more than its last 4 quarters average of 3.8

Amphastar Pharmaceuticals's revenue has increased by 24% YoY and by 11% QoQ

How efficient is Amphastar Pharmaceuticals business performance

The ROE has grown by 49% YoY and by 27% from the previous quarter

The ROS has grown by 48% YoY and by 26% from the previous quarter

The ROIC is up by 24% year-on-year and by 16% since the previous quarter

The company's return on assets rose by 12% YoY and by 8% QoQ

What is AMPH's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for AMPH.

How did Amphastar Pharmaceuticals financials performed over time

The total assets is 63% greater than the total liabilities

The total assets has surged by 113% year-on-year and by 12% since the previous quarter

Amphastar Pharmaceuticals's quick ratio has surged by 51% QoQ but it has decreased by 36% YoY

AMPH's debt is 13% greater than its equity

AMPH's debt is up by 27% since the previous quarter

Amphastar Pharmaceuticals's debt to equity has increased by 26% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.